A non-interventional, real-world study of HRRm testing, treatment patterns, and overall survival among patients with metastatic castration-resistant prostate cancer initiating treatment with talazoparib plus enzaluatime in the US. First published 27/10/2026 Last updated 27/10/2026 EU PAS number:EUPAS1000000963 Study Ongoing